• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HMD
Click for more information
0.00% 2.3¢

HERAMED LIMITED - Corporate Spotlight

Market Cap $14.56M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Medical Devices

Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for... Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for home and professional use. It offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The Company also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.More

No Corporate Spotlight currently available.

(20min delay)
Last
2.3¢ 		Change
0.000(0.00%) 		Mkt cap ! $14.56M
Open High Low Value Volume
2.3¢ 2.4¢ 2.3¢ $5.934K 249.2K

Buyers (Bids)

No. Vol. Price($)
3 1792299 2.3¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 289978 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
Last
2.4¢ 		  Change
0.000 ( 4.35 %)
Open High Low Volume
2.3¢ 2.4¢ 2.3¢ 211090
Last updated 15.59pm 28/06/2024 ?
HMD (ASX) Chart

Top Stories

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Lithium Universe is here today to provide an update on its most recent visit to the Becancour Project in North America. I'm joined by the company's CEO, Alex Hanly.
Recce's R327 found effective against E.coli during clinical trial Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom Wealth Within's Dale Gillham weighs in on the shock 4% inflation read from the ABS midweek – and stocks that could survive the gloom.
Microcap Wrap: 5 explorers with news out today Taking a look around the market at five different announcements out today from microcap junior explorers in Australia.
Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker The biggest story of this week was the surprise 4% inflation rate posted by the Australian Bureau of Statistics (ABS) midweek. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.